Important Notice Regarding Least Costly Alternative for Drugs Billed to the Medicare Carrier

Effective April 19, 2010, the least costly alternative (LCA) policy for drugs billed to the Medicare carrier will be suspended. The National Government Services Local Coverage Determination (LCD) for Luteinizing Hormone Releasing Hormone (LHRH) (L26369) is the only National Government Services policy pertaining to Part B providers with LCA information. This policy will be retired and replaced as a coverage article attached to the National Government Services LCD for Drugs and Biologicals, Coverage for Labeled and Off-Labeled Indications (L25820). This article will not contain LCA provisions.

The Centers for Medicare & Medicaid Services (CMS) Internet-Only Manuals (IOMs) will be revised by CMS in the near future.

Questions regarding this educational article may be directed to the Clinical Provider Outreach and Education Department at clinical.education@wellpoint.com.

This entry was posted on Wednesday, May 12th, 2010 at 10:50 am and is filed under MEDICARE UPDATES. You can follow any responses to this entry through the RSS 2.0 feed. Responses are currently closed, but you can trackback from your own site.